01—Abstract
Summary
Summary of the 8-K filed December 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Elevance Health (NYSE: ELV) filed an 8-K on December 10, 2025 to disclose a board appointment rather than any financial results, operational update, or transaction.
The Board elected Amy W. Schulman as an independent director effective January 12, 2026, with a term expiring at the 2028 annual meeting. She was also appointed to the Audit and Finance Committees, and the Board determined she qualifies as an independent director under NYSE standards and as an audit committee financial expert under SEC rules.
For investors, the filing is primarily a governance event. Adding a director with audit committee financial expert status strengthens oversight of financial reporting, which can be viewed favorably given the scrutiny managed care companies face over medical cost trends, reserve accuracy, and internal controls. The company frames the move as part of an ongoing board refreshment strategy.
The filing discloses no compensation beyond the standard non-employee director program, no related-party transactions, and no arrangements tied to her election. The filing does not change Elevance's financial outlook, guidance, capital allocation, or risk profile. Investors should treat it as a routine but relevant governance update, and look to the company's periodic reports and earnings disclosures for financial performance indicators.
02—Key points
Key Highlights
- Amy W. Schulman elected as independent director effective January 12, 2026, with term expiring at the 2028 annual meeting
- Appointed to both the Audit and Finance Committees
- Board determined Schulman is an 'audit committee financial expert' under SEC rules and independent under NYSE standards
- Background includes Managing Partner at Polaris Partners (over $4B in healthcare and technology investments), Chair of Alnylam Pharmaceuticals, and former Pfizer General Counsel and EVP
- No arrangement or understanding with any other person regarding her election; no material related-party interest under Item 404(a)
- Compensation follows the standard non-employee director program, previously filed as Exhibit 10.7 to the Q2 2025 10-Q
- Filing contains no financial results, guidance changes, or material transactions
03—Questions
Frequently Asked Questions
Does this filing change Elevance Health's financial outlook?
No. The 8-K only reports a board appointment. It contains no financial results, guidance updates, or transaction disclosures that would affect the company's financial outlook.
Why does Amy Schulman's audit committee financial expert designation matter?
The designation means the Board has determined she has the financial sophistication required under SEC rules to oversee financial reporting. This can strengthen audit committee oversight of matters such as internal controls and financial disclosures.
When does Ms. Schulman's board service begin?
Her service is effective January 12, 2026, and her term runs until the Company's 2028 annual meeting of shareholders.
Is Ms. Schulman's compensation different from other non-employee directors?
No. The filing states she will receive compensation under the Company's standard program for non-employee directors, which was previously disclosed as Exhibit 10.7 to the Q2 2025 Form 10-Q.
Does Ms. Schulman have any conflicts of interest disclosed in the filing?
The filing states she has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no arrangement or understanding with any other person in connection with her election.
04—Continue